(NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an ...

The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The awards are being granted as an inducement material ...

Nasdaq has informed the Company that it must submit a plan to regain compliance with respect to the filing requirement by July 21, 2025. If the plan is accepted, Nasdaq can grant an exception of up to ...

Total number of securities carrying voting rights: 37,429,265 (all ordinary shares) Total number of voting rights (= denominator): 37,429,265 (all relating to ordinary shares) ...

HALIFAX, Nova Scotia, May 23, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”) announced today that its shareholders voted in favour of all items of business ...

Austin, TX, May 23, 2025 (GLOBE NEWSWIRE) -- Outliyr, a performance health brand known for combining modern biohacking with ...

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary ...

The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing.

A live audio webcast of the events will be available online at Events & Presentations. An archived replay of PMV Pharma’s presentations will be available for 90 days following the webcast at Events & ...

Cross Medical Group is pleased to announce that HydraFacial treatments are now available at the practice. A HydraFacial at their Philadelphia and Villanova offices, which is sometimes referred to as ...

Chris Taves, Chair of MediPharm, commented: “The troubling fact pattern involving three of the Dissident Nominees raises several red flags. The MediPharm Board urges its shareholders to exercise a ...

U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical tri ...